Aug. 3, 2007 (M2 Communications Ltd. delivered by Newstex) --

Research and Markets ( http://www.researchandmarkets.com/reports/c64757) has announced the addition of Novartis: Performance, Products, Pipeline and Potential to their offering

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of itscccccccclatest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness sector and the sale of the remaining activities of the Industry division, Novartis has become a leading company in the life sciences field and has operations in approximately 140 countries worldwide. Novartis is currently organised into the four divisions of Pharmaceuticals, Consumer Health, Sandoz and Vaccines & Diagnostics, created following the acquisition of Chiron Corporation. Within Pharmaceuticals, the company's current growth drivers include Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and Zometa (zoledronate).

Novartis' current pharma growth drivers together account for approximately 38 per cent of total pharma sales, and we predict that Diovan, Glivec/Gleevec and Zelmac/Zelnorm will continue to demonstrate substantial sales growth within the medium term. In addition, the recent launch and approval of a selection of products which include Exjade (deferasirox), Prexige (lumiracoxib), Xolair (omalizumab), Exforge (valsartan+amlodipine), Lucentis (ranibizumab) and Tekturna (aliskiren), should offset the decline in sales of a number of Novartis' strategic products. However, this confidence is tempered by the recent setbacks to the fortunes of Zelnorm/Zelmac (tegaserod) and Tekturna.

As a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharma pipeline with a total of 138 compounds under development. Of particular note are: Galvus (vildagliptin), filed for Type II diabetes in the US and the EU; and fingolimod under Phase III development for multiple sclerosis. However, Novartis still faces some hurdles since the approvable letter for Galvus has allowed Merck's Januvia a head start in the important US market.

Novartis' major company strategy is based on innovation and achieving a leading position in the healthcare sector. To this end, in 2005, the Pharmaceuticals division further expanded its research operations and this process continued in 2006. Pharmaceuticals remains Novartis' largest and most profitable business, with the Cardiovascular and Oncology franchises continuing as the leading therapeutic areas. Chiron's pharmaceutical operations are being integrated into the Pharmaceuticals division.

In the light of government cost containment measures, Novartis intends to develop new growth platforms such as vaccines (which will reduce costs through disease prevention) and expand its generic business (so capitalising on governments' promotion of generics).

This new strategic analysis report Novartis: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.

EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting

Cardiovascular and Metabolism

Diovan/Co-Diovan (valsartan)

Exforge (amlodipine+valsartan)

Lescol (fluvastatin)

Lotrel (amlodipine+benazepril)

Tekturna (aliskiren)

Oncology/Haematology

Exjade (deferasirox)

Femara (letrozole)

Glivec/Gleevec (imatinib)

Sandostatin (octreotide)

Zometa/Aclasta (zoledronic acid)

Neuroscience

Comtan (entacapone)

Exelon (rivastigmine)

Ritalin/Focalin (methylphenidate)

Stalevo (entacapone)

Trileptal (oxcarbazepine)

Arthritis/Bone

Miacalcic/Miacalcin (synthetic salmon calcitonin)

Prexige (lumiracoxib)

Voltaren/Cataflam (diclofenac sodium)

Gastrointestinal

Zelnorm/Zelmac (tegaserod)

Respiratory/Dermatology

Elidel (pimecrolimus)

Foradil (formoterol fumarate)

Lamisil (terbinafine)

Xolair (omalizumab)

Transplantation/Immunology

Certican (everolimus)

Sandimmun/Neoral (ciclosporin)

Infectious Diseases

Famvir/Denavir (famciclovir)

Sebivo/Tyzeka (telbivudine)

Ophthalmics

Lucentis (ranibizumab)

Visudyne (verteporfin)

OPERATIONAL DATA

A wealth of background and detail

A full 5-year financial performance assessment

Key corporate events

Key agreements

Infrastructure

Subsidiaries

For more information visit  http://www.researchandmarkets.com/reports/c64757

Source: Espicom Business Intelligence

(Comments on this story may be sent to  tww.feedback@m2.com)


Newstex ID: MCOM-0001-18828037

Delivered by Newstex LLC
via theFinancials.com

Giuen Media
Advertising Agency
Sales and Promotion
 http://giuen.wordpress.com